Summary Nebulisation chemotherapy, a chemotherapeutic method for the treatment of lung cancer that involves the administration of anticancer agents through the inhalation of nebulised aerosols, has been found to be highly effective (Tatsumura et al., 1983a,b). We confirmed that 5-FU administered by this method accumulates in the trachea, bronchi and regional lymph nodes of patients treated before surgery, along with 5-FU metabolites, FUR and FUdR, indicating that 5-FU is directly incorporated and metabolised in the respiratory tract. Parallel result were obtained using mongrel dogs. The 5-FU levels in other organs, such as the heart and liver, were found to be extremely low. Only a trace of 5-FU was found in the serum of both the patients and the dogs. We further investigated the anti-tumour effect of this therapy in ten selected patients and observed a satisfactory anti-tumour response of 60.0%. These results, along with our previous finding that the retention time of isotope tracers inhaled as aerosol is considerably longer in tumour tissues than in normal parts (Tatsumura et al., 1983a) al., 1983a,b). The present study further supports the therapeutic value of this method and presents some data which help explain how this therapy works.
Summary Nebulisation chemotherapy, a chemotherapeutic method for the treatment of lung cancer that involves the administration of anticancer agents through the inhalation of nebulised aerosols, has been found to be highly effective (Tatsumura et al., 1983a,b) . We confirmed that 5-FU administered by this method accumulates in the trachea, bronchi and regional lymph nodes of patients treated before surgery, along with 5-FU metabolites, FUR and FUdR, indicating that 5-FU is directly incorporated and metabolised in the respiratory tract. Parallel result were obtained using mongrel dogs. The 5-FU levels in other organs, such as the heart and liver, were found to be extremely low. Only a trace of 5-FU was found in the serum of both the patients and the dogs. We further investigated the anti-tumour effect of this therapy in ten selected patients and observed a satisfactory anti-tumour response of 60.0%. These results, along with our previous finding that the retention time of isotope tracers inhaled as aerosol is considerably longer in tumour tissues than in normal parts (Tatsumura et al., 1983a) explain the high antitumour action of this therapy and the absence of adverse effects of administered 5-FU.
In cancer chemotherapy, the ideal treatment involves the administration of high concentrations of anticancer agents directly and continuously to the target tumour tissue, allowing the agents to exert their maximum cytocidal effects on the tumour without adversely affecting the other organs. A new chemotherapeutic method called 'nebulisation chemotherapy' (NC therapy) was developed for this purpose. This therapy involves the inhalation of ultrasonically nebulised aerosol particles of anticancer agent through the oral cavity and bronchial tree. The technique allows direct and prolonged action of high concentration 5-FU on the tumour tissue of lung cancer. Previous studies have reported strong responses by patients to this form of therapy (Tatsumura et al., 1983a,b) . The present study further supports the therapeutic value of this method and presents some data which help explain how this therapy works.
Materials and methods
Administration and analysis of 5-FU in mongrel dogs The concentrations of 5-FU and its metabolites, FUR and FUdR, in the tissues and sera were measured using a recently developed, high-performance liquid chromatographic (HPLC) method (Masuike et al., 1985) .
Eighteen mongrel dogs weighing 15.5-16.5 kg were used in the experiment. All dogs were anaesthetised with ketamine hydrochloride (Ketalar) (10-20 mg kg-') and atropine sulfate (0.03-0.04 mg kg-'). They were then intubated, mechanically ventilated, and given supplementary oxygen. Anaesthesia was maintained by an intravenous administration of pentobarbital (5-10 mg kg-'). The inhalant was prepared by mixing 5-FU (50 mg kg-') with expectorant, was nebulised by an ultrasonic nebuliser, and was then sent into the respiratory apparatus. Oxygen was supplied to the circuit at a rate of 2 1/min and ventilation was carried out at 100-150 ml min-' at 20 times/min. This circuit carried the aerosol to the bronchial trees at the alveolar level.
Cardiac arrest was induced by an intravenous injection of KCI after each procedure. Tissue samples were collected after Five of the ten cases had primary main bronchial carcinoma, showing invasion to the carina and/or into the contralateral side main bronchi. All of these cases involved squamous cell carcinomas, including two cases with metastatic lymph nodes of primary lung cancer, showing direct invasion of the metastatic nodes to the carina. One case was squamous cell carcinoma and the other case was adenocarcinoma. Two of the others were primary squamous cell carcinomas of the right and left upper lobes that showed invasion to the main bronchi. The remaining case was a recurrence of a bilateral metastatic lung cancer resulting from postoperative adenocarcinoma of lung cancer. Metastatic lesions were noted in the remaining portions of the left lower lobe, and the upper and lower portions of the right lobe. In this series, there were nine males and one female, ranging from 54 to 76 years of age, with a mean of 67.0 years.
The patients were given a mixture of 5-FU and Bisolvon (1-2 ml), vaporised by a supersonic nebuliser. The 5-FU used in this treatment was the same solution generally prepared for intravenous injection (250 mg/5 ml per vial). The aerosol was inhaled through the mouth into the trancheobronchial trees for 10-15 min per treatment. Inpatients received this therapy twice a day on 2 to 3 days per week. The one outpatient in this series was treated once per visit, which was once per week. A standard dose of 250 mg of 5-FU per day was applied. Before each treatment, the patient was required to gargle with milk to prevent stomatitis that might be induced by 5-FU. After each therapy, the oral cavity was rinsed thoroughly with tap water to remove excess 5-FU in the buccal membrane. The treatment was given in a room equipped with a ventilating device to clear away excess 5-FU aerosols. The output of the aerosols is adjusted through the nebuliser apparatus to an adequate volume to inhale, so to minimise the leakage of the 5-FU aerosols during the therapy.
Results Table I summarises the results of the 5-FU series performed on the dogs. High concentrations of 5-FU were detected in the tracheal wall and the bronchial wall of the hilar region in the dogs treated by NC therapy. The 5-FU concentration in the trachea decreased with time. However, the concentration in the hilar bronchi showed an increase that was maintained even after 4 h post-treatment. In contrast, the concentration of 5-FU in the peripheral lung tissue was only roughly one-tenth of the levels in the trachea and bronchi of the hilar region.
The highest levels of 5-FU in the lymph nodes were detected in the peribronchial regions of the right and left main The serum concentration of 5-FU in dogs was 0.27 0.11 jig ml-' after 5 min, 0.30 ± 0.09 jig ml -', after 10 min, and 0.23 ± 0.13 jig ml-', at the end of the 15 min treatment. The concentrations of 5-FU gradually decreased to below the limit of quantitation, between 30 min (0.02 ± 0.02 jig ml-') and 45 min (0.01 ± 0.02 jig ml-') after the end of treatment.
Relatively high levels of 5-FU were found in the esophagus (presumably due to swallowing during therapy) the stomach, and the liver. In the myocardium, the highest concentration was only 0.02 ± 0.02 ig g-'. However, in the pancreas and spleen, the 5-FU levels were below the quantitation limit. The concentrations of 5-FU in the regional lymph nodes were also marked, showing higher levels in the hilar region than in the mediastinal nodes (Table III) . 5-FU was not detected in any of the blood samples that were obtained during surgery, at the time the related tissues were removed.
Six of the ten patients who were subjected to this therapy, showed some response, with two showing a complete response (CR) (Figure 1) , and four showing a partial response (PR). The remaining four cases showed no detectable improvement during the treatment period. Three of these patients died of their disease due to dissemination, and therapy had to stop in last case due to a general deterioration of the patient's condition from dissemination of the disease. Only 1750 mg of 5-FU had been administered by the time the treatment was stopped. The CR cases were administered a mean of 11,750 mg 5-FU (range 10,500-13,000 mg) and the PR group was administered a mean of 5875 mg (range 4750-7520 mg) ( (Task Group on Lung Dynamics, 1966; Wolfsdorf, 1969) . Other studies have CR: complete disappearance of the tumour; PR: a reduction of greater than 50% in the size ofthe greatest perpendicular diameter ofthe tumour; NC: no significant change in the size of the tumour.
shown that this therapy, when clinically applied, can be remarkably efficient, presumably because of the high local concentration and prolonged, constant action by 5-FU on the tumour tissue (Tatsumara et al., 1983a,b) .
The results obtained in this study regarding the distribution of 5-FU in the organs of dogs revealed not only high concentrations of 5-FU in the walls of the trachea and bronchi but also the presence of the metabolites of 5-FU, FUR, and FUdR in the tissues. This clearly indicates that 5-FU is directly incorporated and metabolised in bronchial epithelial cells. It is reasonable to expect that 5-FU is also absorbed by the cells of tracheal and bronchial carcinomas in a similar manner and that this route of administration is more efficient than existing methods. In fact, the 5-FU concentrations found in the tumour tissue were 5-15 times higher than those in the surrounding normal tissue, a level that has not been attained by conventional intravenous or per os methods of administration.
The antitumour effects of 5-FU have been shown to take place at a level of 0.05 mg g' tissue (Eguchi et al., 1979) . The mean 5-FU level found in this study after 4-6 h in the tumour tissue of patients treated preoperatively was 0.086 mg g' tissue, which exceeds this effective level and is in accordance with the high efficacy observed. Using isotopes in the inhalation scanning method, we have previously shown that the ciliary movement of bronchial trees is disturbed by the presence of tumours exposed on the lumen of the respiratory tract, which can retard the excretion function (Tatsumura et al., 1983a) . This physiological phenomenon is an important factor in the present method of therapy because it allows the prolonged contact of highconcentration anticancer agents within the tumour tissue. Furthermore, the destruction of bronchial cilia by the tumour would allow 5-FU to accumulate at the site for a longer period, resulting in a higher intake by the tumour cells.
It is known that 5-FU is a carcinostatic agent and that its action is dependent or cell cycle and time (Skipper et al., 1970) , and, further, that its incorporation into the cell is increased if the cell has been grown in a medium that is rich in 5-FU. When normal ciliary movement has been disrupted, 5-FU can become localised and sustains its contact on the cancerous tissue which may be another factor explaining the efficacy of the present method.
The present results show that, following treatment, there are relatively high levels of 5-FU in regional lymph nodes, in both human patients and in dogs. This suggests that 5-FU was absorbed in the bronchial tree and into the lymphatic path. Therefore, the present method also might be useful in the clinical treatment of metastatic lymph nodes in cases of lung cancer. However, in order to insure that high concentrations of the 5-FU aerosols reach the tumour tissue during therapy, inhalation of the aerosols should be properly performed with periodic and repeated deep inspiration. If inhalation is not properly performed, then the 5-FU aerosols will be confined to the oral cavity or to the laryngopharyngeal region, and the desired anti-tumour effect will not be obtained.
Previous studies have shown that 5-FU increases the radiosensitivity of tumour cells, when applied concomittantly with radiotherapy (Bruce, 1967; Collin et al., 1962; Bagshaw, 1963; Lowry, 1965; Hodnett, 1970) . The combination of these two therapies would be highly effective and may allow a reduction in the radiation dose that is normally applied.
The potential side effects of this therapy to the bronchial tree were evaluated with a routine bronchoscopic study during the therapy, in all of the clinical cases. To date, no occurrence of bronchitis, ulceration of the normal bronchial trees, or pneumonitis has been detected. Furthermore, there has been no hazardous complication of the respiratory tract in those patients treated in our department or in the related hospital, as preoperative therapy or as adjuvant therapy for inoperable cases. It appears that 5-FU inhalation is well tolerated by the bronchial tree and normal lung tissue.
No systemic hazardous effects related to this therapy have been clinically observed. This is verified by the extremely low level of 5-FU in blood after the therapy (Tatsumara et al., 1983a) . Several cases of stomatitis were experienced in the early phase of treatment but this complication was entirely eliminated by instructing the patient to moisten the oral cavity with milk and by gargling after the treatment.
From a clinical standpoint, this therapy provides various advantages beyond the absence of side effects. It requires only a simple and inexpensive ultrasonic nebuliser apparatus and requires only 15 min for single administration, resulting in significant saving in both expenses and time.
Conclusion
The results of analysis on tissues and sera of experimental dogs and preoperative cancer patients for 5-FU and metabolites administered by NC therapy revealed especially high concentrations of 5-FU in tumour tissue and in lymph nodes. The anti-tumour effects of this therapy have also been reconfirmed by the present cases. These observations supported and explained the high efficacy of this therapy for lung cancer, as previously reported and appear to justify the wider use of this method.
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